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Dendritic cells (DCs), specialized antigen-presenting cells bridging innate and adaptive immunity, play a crucial role
in determining specific immune response to tumors. Because of their potent immunoregulatory capacities, DCs
have been exploited in anticancer vaccination, with limited success thus far. This pilot study compared low-dose
interleukin (IL)-4 and IL-12 prepared by sequential kinetic activation (SKA) with standard doses of the same
recombinant human cytokines on functional activity of ex vivo–generated monocyte-derived (Mo) DCs from colon
carcinoma patients and normal subjects. MoDCs were exposed to medium alone, SKA-IL-4 (0.5 fg/ml), or SKA-IL-
12 (2 fg/ml), alone or consecutively combined, in parallel with rhIL-4 (50 ng/ml) and rhIL-12 (1 ng/ml). Primary
allogeneic one-way mixed lymphocyte reaction (MLR) was the end point to assess in vitro T-lymphocyte
proliferation in response to MoDCs, and secreted IL-12p70 and interferon-γ in MLR supernatants measured by
ELISA to assay for T-helper 1–promoting MoDC phenotype. No single agent enhanced the compromised
allostimulatory activity of MoDCs from colon cancer patients, unlike healthy donors. However, MoDCs from
nonmetastatic colon cancer patients, after sequential exposure to SKA-IL-4 (48 hours) and SKA-IL-12 (24 hours),
displayed increased T-cell stimulatory capacity by MLR and acquired driving T-helper 1 polarization activity,
although less markedly than the effects induced by recombinant human cytokines or found in normal subjects.
These results point to an immunomodulatory capacity of low-dose SKA-IL-4 and SKA-IL-12 and encourage further
investigation to provide clues for the rational development of new and more effective immunotherapeutic
strategies against cancer.
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Dendritic cells (DCs) were originally considered to be the most
potent professional antigen-presenting cells (APCs), which can
uptake, process, and present different types of antigens to
antigen-specific naïve T cells, linking the innate and adaptive
immune systems [1]. However, recent work has established that
DCs are a specialized group of APCs with high functional plasticity
[2], which express immunostimulating or immunosuppressive
potential, or both, depending on the consequence and combination
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differentiation, maturation, activation, and polarization [3].
Because of their ability to conduct all of the elements of the
immune orchestra, DCs have long been considered a fundamental
target and tool for cancer immunotherapy. Cancer cells are not
immunologically silent: they can express a wide range of common
tumor-associate antigens, which raise both CD4+ and CD8+ T cells
[4]; DCs, which are found in most human tumors, can sample tumor
antigens by capturing dying tumor cells and by “nibbling” live tumor
cells [5].
DCs, generated ex vivo by culturing hematopoietic progenitor
cells or monocytes (MoDCs) with cytokine combinations, have
been under test as therapeutic vaccines in cancer patients for more
than a decade [6]. Numerous studies, both preclinical experimental
models and human clinical trials, have concluded that DC-based
vaccines are safe and may induce expansion of circulating CD4+
T cells and CD8+ T cells, which are specific for tumor antigens. The
clinical response takes time to build up, but remission can be very
long-lasting [7]. However, the overall clinical success of cancer
immunotherapy is rather low. Tumors usually return, escaping from
the immune system by using a variety of mechanisms, including
switching the differentiation of monocytes to macrophages rather
than DCs [8]; inhibiting DC maturation by secreting interleukin
(IL)-10 [9], which leads to antigen-specific anergy; or inducing “pro–
tumor growth” DCs.
In an attempt to improve the efficacy and outcome of DC-
based cancer vaccines in human cancer immunotherapy, the therapeutic
use of DC cell activators, such as IL-12, IL-15, IL-18, IL-21, and
interferons (IFNs), has been also applied in a clinical context. However,
only modest clinical success has been achieved thus far, as many patients
experienced severe life-threatening toxic side effects [10].
Despite advances in screening and preventative strategies, colorectal
carcinoma (CRC) remains one of the leading causes of cancer-related
death in the Western world [11]. Radical surgical resection of the
primary colorectal lesions, combined with adjuvant chemotherapy and
radiation, when indicated, still remains the mainstay of therapy.
However, approximately 30% of patients are diagnosed with metastatic
disease at initial presentation, and an additional 25% to 30% of patients
will subsequently develop advanced disease, primarily with metastases
to the liver and lungs. The median survival for all patients with
metastatic CRC is approximately 22 to 24months, with 5-year survival
still b5% [12,13].
As with other tumors, immunotherapy also held great promise in
the scenario of potential new approaches to the treatment of CRC
refractory to conventional therapies. Although some clinical trials
using DC vaccines to elicit antitumor immunity in patients with
metastatic CRC were found to be safe and led to positive
immunologic end points, clinical response only occurs in a minority
of patients [14,15]. It might thus be of interest to investigate the
functions of DCs in the tumor bed in the hope of “rewiring”
protumor DCs to become antitumor DCs; this might lead to a novel
approach to cancer immunotherapy.
Several lines of evidence suggest that low-dose cytokines are
adequate for modulating the immune response in many different
models [16]. Recent in vitro studies have shown that low doses of
IL-12 modulate functional activities of T-cell subpopulations from
non–small-cell lung cancer patients [17]. In particular, cytokines
activated by the pharmaceutical preparation process known as
“sequential kinetic activation” (SKA) have been found to retaintheir functional activities even at physiological low-dose concentra-
tions both in a murine model of allergic asthma [18] and in an ex vivo
study of the cytotoxicity of natural killer (NK) cells from CRC
patients [19].
These findings encouraged us to investigate whether this
preparation method might make relevant cytokines as active at low
doses, in DC-based treatment of human cancer, as the high
concentrations normally used in clinical pharmacology but without
the side effects typical of high doses. This explorative study used
ex vivo–generated MoDCs, from healthy donors and from colon
carcinoma patients, to assess in vitro whether single or sequentially
combined exposure to very low doses of SKA-IL-4 and/or SKA-IL-12
might enhance the DCs’ antigen presentation capacity compared with
the normally administered conventional dose of recombinant human
(rh)IL-4 and rhIL-12.
Materials and Methods
Reagents
SKA-IL-4 and SKA-IL-12 were prepared by GUNA Laboratories
(GUNA S.p.a, Milan, Italy) using a standardized method. Cytokines,
sequentially diluted in saline solution (serial dilution 1:100),
underwent a shaking process (vertical shaking; 10-cm motion
range; shaking speed 100 oscillations over 10 seconds, kinetically
energized by a mechanically applied force) [18]. The preparation was
supplied at a concentration of 10−8 μg/ml. rhIL-4 and rhIL-12 were
from PeproTech Inc. (Rocky Hill, NJ).
Patients
The study group comprised 16 patients (10 male, 6 female; median
age, 73; range, 57-83) who had received a diagnosis of colon
carcinoma from the Department of Surgical Medical Sciences at
“Città della Salute e della Scienza” Hospital, Turin (Italy), between
April 2011 and May 2013. Nine patients had histopathologically
confirmed primary colon carcinoma and were staged by Dukes’
system, revised by Astler and Coller (two Dukes’ A and seven Dukes’
B) [20]. Entry criteria were primary colon carcinoma indicative of
surgery with no preoperative evidence of distant metastasis. Seven
patients had histopathologically confirmed metastatic colon carcino-
ma (Dukes’ C with lymph node metastasis). To avoid pharmacolo-
gical and operative interferences that might alter DC activity, none of
the patients had undergone surgical or other anticancer treatment at
the time of blood sampling. A group of 12 healthy donors was used as
controls (6 male, 5 female; median age, 64; range, 37-85). All subjects
provided their informed consent before entering the study. The study
procedures complied with the Helsinki Declaration.
Cell Isolation, DC Generation, and Treatments
Peripheral blood (PB) samples (15 ml) were collected in
anticoagulant-coated tubes from colon carcinoma patients and
healthy donors. PB mononuclear cells (PBMCs) were isolated using
Ficoll-Hypaque density gradient centrifugation. The cells were
resuspended in PBS and 1% human albumin and positively selected
with anti-CD14 monoclonal antibody–conjugated immunomagnetic
beads and MACS Separation columns (Miltenyi Biotec GmbH,
Germany) following the manufacturer’s instructions. The resulting
cells [N95% CD14+ cells, determined by flow cytometric analysis
(Coulter Epics XL; Beckman Coulter, Inc., Fullerton, CA)]. To
generate MoDCs, CD14+ cells were cultured at a concentration of
5 × 105 cells/ml in a 24-well tissue culture plate (Nunc, Roskilde,
Figure 1. (A) MoDC allostimulatory activity of colon carcinoma
patients (n = 16) versus healthy donors (n = 12). (B) MoDC
allostimulatory activity of nonmetastatic (n = 9) versus metastatic
(n = 7) colon carcinoma patients. MoDCs, generated by culturing
PB CD14+ cells from tumor and normal subjects in the presence of
rhGM-CSF and rhIL-4 for 6 days, were incubated with 1 × 105
allogeneic naïve CD4+ T cells at 1:40, 1:20, and 1:10 ratios for
5 days followed by a 6-hour pulse of 3H-TdR. Results are expressed
as mean ± SE cpm of triplicate co-cultures. Statistical significance
was determined using one-way ANOVA.
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calf serum (Sigma Aldrich, St. Louis, MO). Rh granulocyte-
macrophage colony stimulating factor (rhGM-CSF; 50 ng/ml) and
rhIL-4 (20 ng/ml) (PeproTech) were added on the initial day of
culture. Cultures were incubated at 37°C in a humidified atmosphere
flushed with 5% CO2 for 6 days. On day 3, one half of the culture
medium was replaced with fresh medium containing growth factors.
After differentiation, cells were harvested, washed, and used for
subsequent experiments. To induce DC stimulation, two different
approaches were used: 1) incubation of MoDCs with the previously
determined optimal dose of rhIL-12 (1 ng/ml) (PeproTech) or with
increasing concentrations of SKA-IL-12 (from 0.25 to 2 fg/ml) or 2)
consecutive addition to MoDC cultures of a high dose of rhIL-4
(50 ng/ml) or SKA-IL-4 (0.5 fg/ml) for 48 hours, and SKA-IL-12
(2 fg/ml) or rhIL-12 (1 ng/ml) for a further 24 hours. After treatment,
cells were harvested, washed, and used for subsequent experiments.
Primary Allogeneic One-WayMixed Lymphocyte Reaction (MLR)
To determine functional activity of MoDCs, MLR was assayed.
Briefly, MLR was assayed in 96-well round-bottom microtiter plates
by adding graded numbers of irradiated (3000 rad) MoDCs
(untreated or treated as reported above) to allogeneic naïve CD4+
T cells (1 × 105) obtained with a CD4+ isolation kit and subsequent
negative selection in combination with anti-CD45RO monoclonal
antibody plus goat anti-mouse IgG Ab-conjugated immunomagnetic
beads (Dynal, Oslo, Norway) at 1:40, 1:20, and 1:10 stimulator
(DCs)/responder (T cells) ratio. After 5 days of coculture at 37°C,
T-cell proliferation was assessed by the uptake of [3H]-thymidine
(TdR) (1.25 μCi per well present for 6 hours; Perkin Elmer,
Waltham, MA). The radioactivity incorporated into DNA was
measured via β-scintillation counting (cpm = counts per minute).
Each MLR culture was performed in triplicate
Generation of Culture Supernatants fromMLRandMeasurement
of IL-12p70 and IFN-γ
MLR culture supernatants were collected before the addition of
3H-TdR, centrifuged at 4°C to eliminate cells, and immediately
stored at −80°C. Levels of IL-12p70 and IFN-γ were simultaneously
measured using Bio-plex/Luminex technology (Bio-Rad, Veenendaal,
the Netherlands). The range of detection sensitivity of the test was
between 0.49 and 32.000 pg/ml.
Statistical Analysis
Differences between nonparametric data sets were examined by the
Mann-Whitney test. Multiple group means were compared by
one-way analysis of variance (ANOVA). The correlation between
different parameters was determined with nonparametric correlation
Spearman R coefficient (Sigmastat 3.1 software; Jandel Scientific, San
Rafael, CA). Significance was set at P b .05.
Results
Basal MoDC Allostimulatory Activity Status in Patients with
Colon Carcinoma and in Healthy Donors
It was first assessed whether MoDC cells from colon carcinoma
patients (n = 16) retained stimulatory aptitude comparable to that of
healthy-donor counterparts (n = 12). Notably, as shown in Figure 1A,
CD4+-naïve T lymphocytes after incubation with allogeneic MoDCs
from colon carcinoma patients exhibited a significantly lower
proliferative response (indicated by 3H-TdR uptake) (almost 10times less) than did those stimulated with normal MoDCs (P ≤ .001).
Colon carcinoma patients thus demonstrated a marked defect in DC
functional activity.
Because a DC functional defect is an important component of the
overall inability of the immune system to adequately respond to
tumor challenge, patients were categorized by disease stage, and their
MoDC allostimulatory capacity was compared and correlated
(Figure 1B). MoDC-induced T-cell proliferation in the primary
MLR assay was significantly lower in colon carcinoma patients with
locally advanced disease (Dukes’ C, n = 7) than it was in patients with
early-stage colon carcinoma (Dukes’ A + B, n = 9) (P = .003).
Moreover, a significant correlation was found between antigen-
presenting activity of DCs and Dukes’ stage (at DC/T ratio = 1:40,
R = 0.533, P = .033; at DC/T ratio 1:20, R = 0.478, P = .0584; at
DC/T ratio 1:10, R = 0.506, P = .0442, Spearman correlation test).
Figure 2. Effect of low-dose SKA-IL-12 versus standard-dose
rhIL-12 on the MoDC allostimulatory activity of colon carcinoma
patients and healthy donors. MoDCs from nonmetastatic colon
carcinoma patients (n = 6) and healthy donors (n = 5) were
untreated (control) or 24-hour–treated with increasing concentra-
tions of rhIL-12 or SKA-IL-12 and then co-cultured with allogenic
CD4+ naïve cells (responders) at various stimulator-to-responder
cell ratios in triplicate. Proliferative response was assessed by
3H-TdR uptake. Results are expressed as mean ± SE cpm.
Statistical significance was determined using one-way ANOVA.
*P b .05, *P b .05, and ***P = .001.
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on MoDC Allostimulatory Activity in Colon Carcinoma
Patients and in Healthy Donors
Inasmuch as immature MoDCs are no longer considered as vaccine
candidates because of their low T-cell activation potential [21,22],
most recent clinical trials used DCs activated by means of individual
or cocktail cytokines associated with inflammation [23].
An exploratory study was thus run to investigate whether low-dose
SKA-IL-12 might be a promising approach to manipulate MoDCs to
elicit the optimal immune response for cancer therapy; the low dose
was compared with standard-dose rhIL-12.
The efficacy of 24-hour treatment with increasing concentrations
of SKA-IL-12 (0.25, 0.5, 1, and 2 fg/ml) or with the standard dose
of rh-IL-12 (1 ng/ml) on allostimulatory activity of CD14+-derived
DCs from nonmetastatic colon carcinoma patients (n = 6) and
healthy donors (n = 5) was evaluated preliminarily by the MLR
assay. As shown in Figure 2A, when MoDCs were pretreated
with rhIL-12 (1 ng/ml) before functional assay, the allostimulatory
activity increased significantly in nonmetastatic colon carcinoma
patients (P = .026), although there was a high variation in
interindividual response; none of the concentrations of SKA-IL-12
used affected APC capacity. In contrast, in healthy donors, the
highest concentration of SKA-IL-12 evaluated (2 fg/ml) significantly
increased the allostimulatory activity of MoDCs in comparison with
untreated MoDCs (P = .034) even if the effect of the standard dose of
rhIL-12 was more marked (P = .001). These results suggest that
MoDCs from nonmetastatic colon carcinoma patients were func-
tionally poorly responsive or unresponsive to low-dose SKA-IL-12–
mediated stimulation; this is presumably because of a defective
expression of IL-12R complex, which nevertheless is sufficient for
pharmacological doses of IL-12 to induce partial correction of MoDC
allostimulatory activity.
Effect of SKA-IL-4 Pretreatment Followed by SKA-IL-12
Exposure versus the Standard Dose of rhIL-4 and rhIL-12 on
MoDC Allostimulatory Activity in Colon Carcinoma Patients
and in Healthy Donors
Consistent with findings that, in the same instance, paradoxically,
IL-4 can influence DC differentiation into a DC1 phenotype that
produces large amounts of IL-12 [24–27] and, in turn, can
autocrinically regulate IL-12R expression in MoDCs [28], it was
next examined whether the poor SKA-IL-12 response of DCs from
colon carcinoma patients could be overcome by combined sequential
treatment with SKA-IL-4 and SKA-IL-12. Therefore, MoDCs,
generated in 6-day culture with rhIL-4 and rhGM-CSF from PB
CD14+ cells of colon carcinoma patients (n = 13, 6 nonmetastatic
and 7 metastatic) and normal subjects (n = 6), were treated for a
further 48 hours in the absence or presence of SKA-IL-4 (0.5 fg/ml)
or rhIL-4 (50 ng/ml) alone, followed by 24-hour exposure to
SKA-IL-12 (2 fg/ml) or rhIL-12 (1 ng/ml); they were then
functionally assessed.
Figure 3 shows that, in colon carcinoma patients, following
exposure to rhIL-4 or rhIL-12, MoDCs significantly increased their
functional activity in comparison with untreated cells (P = .025 and
P = .006, respectively). After sequential treatment with rhIL-4
(48 hours) and rhIL-12 (24 hours), MoDCs from tumor subjects
became more potent MLR stimulatory cells than did untreated
MoDCs (P b .001). By contrast, in MoDCs from patients, treatment
with SKA cytokines alone did not significantly enhance their APCactivity in MLR in comparison with untreated cells (SKA-IL-4: P =
.172; SKA-IL-12: P = .178) even if, after sequential treatment
with SKA-IL-4 (48 hours) and SKA-IL-12 (24 hours), MoDCs
from tumor subjects became somewhat more potent MLR
stimulatory cells than did untreated MoDCs, approaching statistical
significance (P = .062).
When patients were subdivided into two groups based on disease
stage (Figure 4), significant increases in APC activity in MLR of
rhIL-4, rhIL-12, or rhIL-4 and rhIL-12 sequentially combined
pretreated MoDCs from early-stage colon carcinoma patients (n = 6,
Dukes’ A and B) were observed in comparison with untreated cells
(P = .034, P = .002, and P = .019, respectively). By contrast,
antigen-presenting activity of MoDCs from colon carcinoma patients
with metastatic lymph nodes (n = 7, Dukes’ C) was enhanced only
Figure 3.MoDCs sequentially stimulated with SKA-IL4 and SKA-IL-12 or rhIL-4 and rhIL-12 increased their capacity to initiate an allogenic
response. MoDCs from colon carcinoma patients (n = 13, 6 nonmetastatic and 7 metastatic) or normal donors (n = 6) were generated
frommonocytes and exposed in the presence of predetermined concentrations of SKA-IL-4 (48 hours) and SKA-IL-12 (24 hours) as single
agents or sequentially in parallel to the rh cytokines, and subjected to MLR with allogeneic naïve T cells in different MoDC-to-T cell ratios.
MLR strength was measured by 3H-TdR incorporation of the co-culture. The plot shows the mean ± SE of 3H-TdR incorporation in cpm.
Statistical significance versus control was determined using one-way ANOVA.*P b .05, **P b .01, and ***P b .001.
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MLR response levels in the presence of MoDCs pretreated with
rhIL-4 and rhIL-12 as single agents, or with rhIL-4 and rhIL-12 in
subsequent association, were significantly lower in colon carcinoma
patients with metastatic lymph nodes than in those with locally
extended tumors (Dukes’ A + B, n = 6) (P = .003, P = .006, P = .004,
and P = .023, respectively).
Interestingly, MoDCs from earlier-stage disease (Dukes’ A + B)
colon carcinoma patients, but not those from metastatic disease
(Dukes’ C), when instructed by sequential SKA-IL-4 and SKA-IL-12
exposure, promoted a significant proliferative response in allogeneic
MLR in comparison with untreated cells (P b .001 and P = .076,
respectively), although their functional recovery did not reach levels of
those from normal subjects (P ≤ .001), whereas the same cytokines
used singly did not affect functional activity of MoDCs in eithergroup (SKA-IL-4: P = .099 and P = .054; SKA-IL-12: P = .149 and
P = .185, respectively). When the two groups of patients were
compared, the levels of MLR responses in the presence of untreated
MoDCs, MoDCs pretreated with rhIL-4 or with rhIL-12 as single
agents, or with rhIL-4 and rhIL-12 in subsequent association were
significantly lower in colon carcinoma patients with metastatic lymph
nodes compared with those with locally extended tumors (P = .004,
P = .001, P = .001, and P b .001, respectively).
In normal donors (Figure 3), both single exposure to SKA-IL-4
(48 hours) and to SKA-IL-12 (24 hours) significantly increased
MoDC MLR-stimulating capacity compared with basal condition
(P = .035 and P = .026, respectively; right-hand panel), although the
effect of the rh cytokines was stronger (approximately double) (P =
.021 and P b .001, respectively; left-hand panel). Both SKA-IL-12
and rhIL-12 were more potent stimulators of MoDC functional
Figure 4. Effects of standard-dose rhIL-4 and/or rhIL-12 and low-dose SKA-IL-4 and/or SKA-IL-12 on APC activity in MLR of MoDCs from
nonmetastatic colon carcinoma patients (n = 6) and from metastatic colon carcinoma patients (n = 7). MoDCs were untreated or
pretreated with SKA-IL-4 (48 hours) and SKA-IL-12 (24 hours) as single agents or sequentially in parallel to the rh cytokines, and subjected
to MLR with allogeneic naïve T cells in different MoDC-to-T cell ratios. The figure shows the mean percentages ± SE of 3H-TdR
incorporation in cpm. Statistical significance was determined using one-way ANOVA.Rh/SKA cytokine pretreated nonmetastatic/
metastatic colon carcinoma MoDCs versus untreated nonmetastatic/metastatic colon carcinoma MoDCs: *P b .05 and **P b
.01.Nonmetastatic colon carcinoma MoDCs versus metastatic colon carcinoma MoDCs: ●●P b .01 and ●●●P b .0001.
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P = .010). When MoDCs from healthy donors were subsequently
exposed to SKA-IL-4 (48 hours) and SKA-IL-12 (24 hours), a
further significant increase in their APC activity in MLR was
observed in comparison to untreated, SKA-IL-4–treated, or SKA-
IL-12–treated MoDCs (P = .021, P b .001, and P b .001,
respectively). However, sequential treatment with rhIL-4 and
rh-IL-12 enhanced MoDC allostimulatory activity more markedly
than with untreated or SKA-IL-4–/SKA-IL-12–treated cells (P b .001
and P = .002, respectively).
T Helper (h) 1 Cytokine Production
The question of the extent to which IL-4– and/or IL-12–treated
MoDCs can actually induce T-helper (Th) 1 cell polarization was
addressed by investigating the profile of cytokines released uponstimulation in allogeneic MLR. It should be stressed that the
cytokines used for pretreating MoDCs were no longer present during
the MLR assay and that cytokine levels reflect both T-cell and APC
cytokine production.
As shown in Figure 5, normal MoDCs (n = 5) cultured in
MLR with naïve CD4+ T cells did not produce any or at
most produced negligible levels of biologically active IL-12p70
(0.313 ± 0.183 pg/ml), whereas rhIL-4–, rhIL-12–, but especially
rhIL-4/IL-12–treated MoDCs secreted IL-12p70 in the pg/ml
range (47.89 ± 20.82 pg/ml, 61.63 ± 22.39 pg/ml, and 205.39 ±
71.64 pg/ml; P vs untreated MoDCs = .041, .024, and .021,
respectively). MoDCs conditioned by SKA-IL-4 slightly increased,
though not significantly, IL-12p70 production in the supernatant of
MLR culture in comparison with the control (23.46 ± 14.79 pg/ml,
P = .111). Conversely, MoDCs treated with SKA-IL-12 alone or
Figure 5. Effects of MoDC treatment with SKA-IL-4 and SKA- IL-12 alone or sequentially combined in priming Th1 response in comparison
to rhIL-4 and rhIL-12. MLR was run by co-culturing untreated and SKA- or rh cytokine–treated MoDCs from normal subject (n = 5) and
from nonmetastatic colon carcinoma patients (n = 6) (C and D) with naive allogeneic CD4+ T cells at stimulator (DCs)/responder
(allogeneic naive allogeneic CD4+ T cells) ratio of 1:40. IL-12p70 and IFN-γwere measured in MLR supernatants by ELISA after 5 days of
co-culture. Data are means ± SE pg/ml of duplicates. Statistical significance was determined using Mann-Whitney test. The P values are
reported in the text.
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secretion (40.45 ± 14.85 pg/ml and 69.53 ± 23.59 pg/ml; P vs untreated
MoDCs = .024 and .029, respectively), but less efficiently than the
counterpart rh cytokine-exposed cells (p = 0.046, p = 0.025, respectively).
Though much less markedly than their normal counterparts,
MoDCs from nonmetastatic colon carcinoma patients (n = 5, sole
group examined) when exposed to rhIL-4 and rhIL-12 as single agent
or to their sequential combination also acquired an enhanced ability
to elaborate IL-12p70 into allogenic MLR compared with untreated
cells (7.13 ± 1.85 pg/ml, 16.74 ± 3.68 pg/ml, 27.95 ± 5.16 pg/ml,
0.34 ± 0.22 pg/ml; P vs untreated MoDCs (0.183 pg/ml) = .018,
.012, and .006, respectively). By contrast, MoDCs from metastasis-
free tumor patients only significantly produced IL-12p70 after
SKA-IL-4/SKA-IL-12 sequential treatment (8.80 ± 2.35 pg/ml; P vs
untreated MoDCs = .028) because both SKA-IL-4 and SKA-IL-12
exposure induced a slight enhancement in IL-12p70 secretion, without
reaching statistical significance (3.036 ± 1.46 pg/ml and 4.98 ±
2.51 pg/ml; P vs untreated MoDCs = .152 and .063, respectively).Regarding the production of IFN-γ, MoDCs from healthy
subjects, cultured in MLR with naive CD4+ T cells, were poor
inducers of IFN-γ secretion (28.56 ± 8.59 pg/ml). However,
MoDCs conditioned by rhIL-4, rhIL-12, or rhIL-4/rhIL-12
induced production of IFN-γ by T cells (266.63 ± 16.11 pg/ml,
492.57 ± 118.01 pg/ml, and 1756.53 ± 204.43 pg/ml; P vs
untreated MoDCs = .021, .029, and .004, respectively). The same
cells exposed to SKA-IL-12 or sequential combination of
SKA-IL-4/SKA-IL-12 (but not to SKA-IL-4 alone) were also
able to induce T cells to secrete significant quantities of IFN-γ
(302.71 ± 54 pg/ml and 578.35 ± 158.36 pg/ml; P vs untreated
MoDCs = .011 and .044, respectively), although to a lesser extent
(P vs rhIL-12– or rhIL-4/rhIL-12–treated MoDCs = .048 and
.004, respectively).
MoDCs from nonmetastatic colon carcinoma patients recovered
only partially, in comparison with normal donors, their capacity
to induce IFN-γ production by naïve CD4+ T cells during MLR
when preexposed to rhIL-4, rhIL-12, or rhIL-4/rhIL-12 [95.45 ±
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untreated MoDCs (11.52 ± 6.51 pg/ml) = .045, .027, and .003,
respectively]. By contrast, exposure of tumor MoDCs to SKA
cytokines had a small but statistically significant positive impact on
IFN-γ secretion by T cells only in the presence of SKA-IL-12 or
double SKA-IL-4/SKA-IL-12 (74.05 ± 12.20 pg/ml and 89.78 ±
15.74 pg/ml; P vs untreated MoDCs = .05 and .038, respectively),
supporting the finding that MoDCs, when activated by sequential
treatment with IL-4 and IL-12, can promote differentiation of naïve
Th cells into IFN-γ–producing Th1 cells.
Discussion
The goals of cancer immunotherapy are to activate and expand
tumor-specific CD4+ and CD8+ T cells as effective means of
augmenting immunity and overcoming mechanisms used by tumors
to evade destruction. To induce a robust antitumor immune
response, peptides derived from tumor-associated antigens must be
presented to T cells by professional APCs, such as DCs, if possible
producing IL-12p70 because of their leading role in promoting Th1
cell polarization [29,30], their innate immunity through induction of
NK cell proliferation, and release of IFN-γ [31].
Most DC vaccination studies have used either immature or mature
DCs, which lack sufficient capacity to secrete biologically active
IL-12p70 [32,33]. Conversely, in vivo manipulation of DCs by a
single administration of IL-12 or by its administration in
combination with different immunomodulatory cytokines, despite
appearing very promising in some clinical trials [34], has unfortu-
nately been associated with a severe degree of toxicity and with the
generation of counterregulatory (i.e., immunosuppressive) measures
that limit their overall usefulness as a cancer therapeutic [35].
Substantial debate still surrounds whether DCs can function as
tumor therapy based on the outcome of numerous clinical studies on
different malignancies, including CRC, the results of which have not
been in line with initial expectations [32].
The question remains of how DCs can be functionally conditioned
more effectively to express immunostimulatory cytokines (IL-12p70)
and co-stimulatory molecules in parallel with antigen presentation to
improve antitumor immune response. Additional investigation is thus
needed to fine-tune this strategy, selecting optimal DC preparation
and/or cytokine dosage schemes.
This explorative ex vivo study found 1) impaired in vitro generation
of fully functional MoDCs from colon carcinoma patients; in
particular, this defect was marked in MoCD from patients with more
advanced disease, and 2) notably, the capacity of sequential exposure
of MoDCs from early-stage colon carcinoma patients to very low
doses of SKA-IL-4 and SKA-IL-12 to improve APC activity in
allogeneic MLR, inducing slightly enhanced (but of potentially
functional significance) IL-12p70 production and also Th1
polarization. These effects were evidenced by IFN-γ release in
MRL supernatants.
Because potential tumor-cell clearance by specific cytotoxic CD8+
T lymphocytes, in addition to NK cells, is part of the mechanism of
action of DC-based immunotherapy, the basal functional state of
DCs may critically influence both response to treatment and clinical
outcome. The poor quality found in MoDCs generated ex vivo from
colon carcinoma patients, further deteriorating at advanced stages of
the disease (activity being approximately 1/10 that of MoDCs from
normal subjects), suggests several limiting pathways that hamper the
capacity of DCs in the tumor microenvironment. Deficiency inexpression of co-stimulatory receptors, poor ability to stimulate T-cell
responses, and altered cytokine secretion have been reported in DCs
from cancer patients [36,37]. Moreover, in CRC patients, the
defective function of DCs from blood precursors cannot be overcome
by removing the tumor immunosuppressive factors, unlike DCs
generated ex vivo from breast cancer patients, which were found to be
fully functional [38].
Clinical evidence reports that these reduced DC functional basal
levels are significantly related to overall survival, progression-free
survival, and response rate [39–41]. Accordingly, the present results,
showing that colon carcinoma exerts negative effects on DC
generation and maturation, suggest a tumor-induced accumulation
of immature cells, with inhibitory function and/or inability to deliver
tumor antigens in a manner that renders them immunogenic to the
host. Such dysfunction has significant implications for both the
induction of natural antitumor immune responses and the efficacy of
immunotherapeutic strategies that target endogenous DCs in situ or
that use exogenous DCs as part of anticancer immunization
maneuvers, and may explain why, to date, immunotherapy trials in
CRC have failed to translate the immune response into an effective
therapeutic outcome.
Emerging evidence points to a developmental and microenvironment-
dependent plasticity of DCs: this is a heterogeneous cell population
in terms of surface phenotype because the precursors themselves are
not uniform. Distinct subsets of DCs have intrinsic differences that
lead to functional specialization, playing significant roles in both
induction of antitumor immunity and support of tumor growth and
progression [42].
Because the available clinical data appear to show that stimulated
MoDCs may provide greater therapeutic benefits versus immature
MoDCs in the cancer setting [6,43–45], to optimize the utility of
DCs in immunotherapy approaches, it is critical to determine
properties, such as phenotype and function, that are correlated with
clinical efficacy and to apply quality control for their presence.
IL-12 is a hallmark inflammatory cytokine capable of eliciting
potent Th1 immune responses [29]. However, recent studies have
provided strong indications of an autocrine activity of IL-12 on DCs;
these have shown the constitutive expression of both IL-12 receptor
(R) β1 and β2 chains on these cells [28,46] and a marked increase in
this expression following cell activation [12,13]. Binding of IL-12 to
its receptor induces a series of intracellular reactions involving the
Jak-Stat signaling cascade; these reactions have a direct impact on
MoDC functions, including enhanced IL-12 production, upregula-
tion of the co-stimulatory molecule CD80, increased capacity to
stimulate T-cell proliferation, and endogenous production of IFN-γ
[47–49], which may affect the development of adaptive immunity
[17,50]. The present assessment of rhIL-12 ponderal dose-pretreated
MoDCs from nonmetastatic colon carcinoma patients’ capacity to
stimulate T-cell proliferation in MLR showed that there was a
significant gain in functional activity, although it was more limited
than that occurring in normal donors.
Because it has recently been found that the SKA pharmaceutical
technique enables low doses of cytokines to achieve the same
biological results as high doses but presumably without the related
opposing and/or side effects [17–19], previous work testing
the potential regulatory activity of SKA-IL-12 was extended to the
APC capacity of MoDCs. MoDCs from nonmetastatic colon
carcinoma patients were found to be unresponsive to SKA-IL12
stimulation or, at most, considerably less than MoDCs from
Figure 6. Schematic representation of the hypothetical mode of
action and consequences of sequential exposure to low doses of
SKA-IL-4 and SKA-IL-12 in comparison with ponderal doses of
rhIL-4 and rhIL-12 on DC IL-12p70 secretory activity.
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functional ability after exposure to the highest of the low doses of the
SKA cytokine (2 fg/ml) used.
This finding further supports the idea that different origins and
environmental signals, produced by neighboring immune cells and by
the tumor itself, may contribute to the induction of unique DC
phenotypes in cancer patients, which will ultimately shape the nature
of the immune response against the tumor [50]. It has been reported
that tumor-infiltrating DCs isolated from CRC express reduced levels
of co-stimulatory molecules (CD80 and CD86) and do not respond
to cytokines (GM-CSF and tumor necrosis factor-α or CD40 ligand)
that normally induce robust expression of these molecules [51].
The lack of SKA-IL-12 response in DCs from colon carcinoma
patients might be due to insufficient IL-12R. It would be interesting
to evaluate the basal and rh or SKA-IL-12–induced phenotype of
MoDCs generated from this series of colon carcinoma patients.
However, the frequency of DC precursors in the PB was low, and a
blood sample of ethically acceptable size did not produce a sufficient
number of cells for both phenotypic and functional studies.
It is clear that DC preparation designed to optimize IL-12p70
production (which presumably is associated with the potent
Th1-skewing potential of DCs in vivo) [52] would be highly
desirable to enhance the effectiveness of tumor immunotherapy.
To date, the majority of DC vaccine studies have used either
immature DCs (GM-CSF/IL-4) or partially matured DCs
(GM-CSF/IL-4 plus activation by IL-1β, IL-6, tumor necrosis
factor-α, and/or prostaglandin-2), which express co-stimulatory
molecules but fail to produce IL-12p70 [53].
IL-4 is widely known for its role in Th2 cell polarization [54], but
the regulatory roles of IL-4 in DC function have been studied in
much less depth. Opposing effects on the development of
DC-mediated immune responses, depending on the time of
application and the concentration used, have emerged from recent
studies. IL-4 induces DC maturation, upregulating expression of
MHC class II molecules, co-stimulatory receptors, and IL-12Rβ1,
which forms the functional high-affinity IL-12 receptor together with
IL12Rβ2 [28,55]. Moreover, IL-4 can also enhance IL-12 production
in DCs [56]: in particular, it has been reported that immature human
DCs activated under high-dose IL-4 produce large amounts of IL-12
and small amounts of IL-10, thus preferentially inducing Th1
differentiation [27]. Based on these findings, it was decided to
evaluate whether sequential exposure of MoDCs to IL-4 (48 hours)
and IL-12 (24 hours) could be a new strategy to develop a
predominant Th1 response, of clear interest in tumor therapy.
Upon sequential rhIL-4/rhIL-12 stimulation, MoDCs from
normal donors displayed an increased ability (almost additive) not
only to induce T-cell proliferation but also to produce higher levels of
biologically active IL-12p70 and to promote IFN-γ release, as
detected by ELISA in MLR supernatants, used as a surrogate to
measure treatment potency and efficacy.
Interestingly, MoDCs from nonmetastatic colon carcinoma
patients, consecutively exposed to rhIL-4/rhIL-12 before the phase
of cognate APC–T-cell interactions, also significantly increased their
allostimulatory and Th1-skewing potential, although to a lesser extent
than with healthy subjects. More importantly, the same effects were
observed when, instead of rh cytokines, SKA-IL-4 and SKA-IL-12
were used to activate MoDCs from both normal donors and
nonmetastatic colon carcinoma patients. As expected, in nonmeta-
static colon carcinoma patients, low-dose SKA cytokines were lesseffective but were still biologically relevant, inasmuch as preexposed
MoDCs improved their functional responses in terms both of naïve
CD4+ T-cell allostimulation and of Th1 priming. In accordance with
other reports [57], the IL-12p70 levels in MLR supernatants were
below the threshold of detection in both patients and volunteers. The
fact that MoDCs from nonmetastatic CRC patients, after sequential
treatment with SKA-IL-4 and SKA-IL-12, can acquire the ability to
elaborate IL-12p70 (at levels that are rather low, but active in
inducing IFN-γ release) might, however, be clinically relevant
because it could avoid DC exhaustion and tolerance while inducing a
persistent and prolonged antitumor immune response (Figure 6).
Increasing evidence demonstrates that pharmacological induction
of antitumor immunity is rapidly counteracted by homeostatic
regulation, resulting in a progressive loss of therapeutic efficacy [58].
Ex vivo studies have shown that potent stimulation driving type-1 DC
polarization, such as high doses of IL-12, induces high-level secretion
of IL-12p70 over a narrow window of time, peaking after 8 to 12
hours and then returning to baseline. This phenomenon, referred to
as “exhaustion,” leads to the loss of DCs’ capacity to prime Th1
immunity and to the generation of Th2-skewed immunity [59].
Moreover, in most patients, repeated injections of standard doses of
IL-12, after initial stimulation of massive production of IFN-γ, led to
an adaptive response and a progressive decline of IL-12–induced
IFN-γ concentration in the blood [60], whereas an objective clinical
response or disease stabilization may occur with the sustained
production of IFN-γ [61].
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involve a complex interplay between different cell types, cytokines, and
recognition receptors. The two-way interactions between DCs and T
cells initiate either an immunogenic or a tolerogenic pathway, both of
which can play crucial roles in tumor immunity [62]. Tumors can
mimic some of the signaling pathways of the immune system, thus
propagating conditions that favor immune tolerance and escaping
tumor immunity [63]. It has been shown, here and in other reports, that
CRC cells can confer tolerogenic behavior on MoDCs by inducing
phenotypic alterations and reducing the ability to stimulate T cells.
However, because these defects persist ex vivo, this would imply not just
a dependency on the local tumor milieu but also recruitment and
accumulation by the tumor products ofDC subsets in the blood stream;
these products selectively promote deleterious mechanisms, such as
inducing tolerance to tumor antigens [64] and/or proliferation of
regulatory T cells that, in turn, prevent immune responses in a
transforming growth factor-β–dependent manner [65].
Immunological or pharmacological therapy that might alter the
proportion of conventional immunogenic versus regulatory DCs in
the tumor environment could efficiently improve tumor-specific
responses in cancer patients. In agreement with these concepts, the
present study provides evidence that, by sequential exposure of
MoDCs from nonmetastatic colon carcinoma patients to IL-4 and
IL-12, it is possible to prime (IL-4) and to boost and maintain (IL-12)
an antitumor Th1 response, taking advantage of each cytokines'
biological functions. IL-4 plays a key role in instructing DCs to
produce less IL-10, thereby favoring Th1 cell differentiation [66].
Bioactive IL-12 and IFN-γ are the critical cytokines initiating the
downstream signaling cascade to develop Th1 cells [67].
DC-based immunotherapy is safe and can induce antitumor
immunity even in patients with advanced disease. However, clinical
responses have been disappointing, with classic objective tumor
response rates rarely exceeding 15% [68]. Many clinical protocols
using ex vivo–generated DC-based vaccines do not consider the fact
that DCs administered to patients with cancer might quickly lose
their activity in the cancer environment. Moreover, DCs that secrete
high levels of IL-12, and thus induce Th1 polarization, are capable of
producing IL-12 for only a short time [59], after which they exhaust
their ability to produce IL-12 and subsequently activate proliferating
T cells toward either a Th2 response or a regulatory T cell response.
Severe side effects associated with the systemic administration
of IL-12p70, together with its very narrow therapeutic index,
have hindered its wider incorporation into investigational cancer
vaccine formulations [69]. Moreover, high-dose cytokine adminis-
tration to cancer patients, rather than stimulating their immune cells
to more effectively kill tumor cells, may have the opposite effect,
driving the immune machinery into burnout: this might partially
explain the negative clinical results of cytokine-based immunotherapy
[58]. Notably, and for the first time, the findings reported here
provide evidence that ex vivo sequential pretreatment with low-dose
SKA-IL-4 and SKA-IL-12 can induce, at least in nonmetastatic colon
cancer patients, an improvement of MoDCs’ ability to stimulate naïve
CD4+ cell proliferation and IFN-γ production in MLR.
In DC-based vaccination against cancer, cytokines play a critical
role both ex vivo, to generate the cell populations used in vaccines,
and in vivo, as adjuvants to these therapies, to augment the potency
and duration of the antitumor response. It may be assumed that low
doses of these SKA cytokines, which can be administered chronically
over long periods without any deleterious side effects [70], could keeptumor growth under control by restoring and maintaining an effective
immune response against tumor cells.
Although the significance of the present ex vivo study is somewhat limited
because of the small number of donor patients, it is nevertheless indicative.
SKA-IL-4 and SKA-IL-12, by virtue of their biological activities at
low-physiological-range doses, most certainly deserve further investigation.
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